Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00687622 · ClinicalTrials.gov registry record · Phase 1
Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 206
- Enrollment target
NCT00687622 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 206 participants.
The verdict
NCT00687622, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 206 participants
- Enrollment target
Study Summary
MEK111054 is a first-time-in-human, open-label study to determine recommended dose and regimen for the orally administered GSK1120212. The study consists of three parts. Part 1 will identify the maximum tolerated dose. Part 2 will explore the safety, tolerability, and effectiveness of GSK1120212. Part 3 will determine a range of effective doses.
Interventions
- DRUG GSK1120212
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2008-07-28 |
| Est. Completion | 2011-11-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00687622
The ClinicalTrials.gov registry entry for NCT00687622 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GSK1120212 is the first listed.
NCT00687622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00687622 about?
NCT00687622 is a clinical study titled "Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma". MEK111054 is a first-time-in-human, open-label study to determine recommended dose and regimen for the orally administered GSK1120212. The study consists of three parts. Part 1 will identify the maximum tolerated dose. Part 2 will explore the safety, tolerability, and effectiveness of GSK1120212. Pa...
What is the current status of trial NCT00687622?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 206 participants. The study started on 2008-07-28. Estimated completion is 2011-11-08.
What interventions are being tested in trial NCT00687622?
The interventions under investigation include: GSK1120212 (DRUG).
Who is sponsoring clinical trial NCT00687622?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.